BIO Stock Overview
Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BIO from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$330.53 |
| 52 Week High | US$387.99 |
| 52 Week Low | US$262.12 |
| Beta | 0.90 |
| 1 Month Change | -0.71% |
| 3 Month Change | 4.75% |
| 1 Year Change | 2.99% |
| 3 Year Change | -55.80% |
| 5 Year Change | -10.67% |
| Change since IPO | 12,833.78% |
Recent News & Updates
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Dec 16
Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Nov 25Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?
Nov 25A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Recent updates
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Dec 16Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Nov 25Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Potentially Undervalued?
Nov 25A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Nov 04Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Sep 23We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Sep 08Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Shares May Have Run Too Fast Too Soon
Jul 18Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Jul 14Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet
Apr 18Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Apr 14At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?
Feb 07Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance
Oct 25Bio-Rad: A Cash Flow Returns On Investments Analysis
Aug 10Bio-Rad Labs reports Q4 2022 results
Feb 16Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals
Jan 04Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M
Oct 27Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal
Oct 12Bio-Rad Laboratories hits 52-week low; down 40% YTD
Sep 19Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M
Jul 28Shareholder Returns
| BIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -2.2% | -1.9% | -2.2% |
| 1Y | 3.0% | -5.3% | 23.9% |
Return vs Industry: BIO exceeded the US Life Sciences industry which returned -5.3% over the past year.
Return vs Market: BIO underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 5.6% |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BIO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 8,030 | Norman Schwartz | www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Bio-Rad Laboratories, Inc. Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | US$9.23b |
| Earnings (TTM) | -US$778.69m |
| Revenue (TTM) | US$2.58b |
3.6x
P/S Ratio-11.9x
P/E RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | US$2.58b |
| Cost of Revenue | US$1.17b |
| Gross Profit | US$1.41b |
| Other Expenses | US$2.19b |
| Earnings | -US$778.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -27.81 |
| Gross Margin | 54.54% |
| Net Profit Margin | -30.18% |
| Debt/Equity Ratio | 15.9% |
How did BIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 22:57 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio-Rad Laboratories, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Jon Wood | BofA Global Research |
| Sel Hardy | CFRA Equity Research |